XML 52 R37.htm IDEA: XBRL DOCUMENT v3.20.4
15. Parent Company Financial Statements (Tables)
 12 Months Ended
Dec. 31, 2020
Condensed Financial Information Disclosure [Abstract]  
Parent Balance Sheets
Assets   2020     2019  
Current assets            
Cash and cash equivalents   $ 318     $ -  
Prepaid expenses     252       290  
Other current assets     -       29  
Total current assets     570       319  
                 
Investment in AE Advanced Products Keyes , Inc.     12       293  
Investment in Aemetis International, Inc.     4,196       3,638  
Total investments in Subsidiaries, net of advances     4,208       3,931  
                 
Property, plant and equipment, net     9       4  
Other assets     2,700       257  
Total Assets   $ 7,487     $ 4,511  
                 
Liabilities & stockholders' deficit                
Current liabilities                
Accounts payable   $ 4,881     $ 5,097  
Payables due to subsidiaries     4,390       3,176  
Mandatorily redeemable Series B convertible preferred     3,252       3,149  
Other current liabilities     11,930       9,217  
Total current liabilities     24,453       20,639  
                 
Long term liabilities:                
Other long term debt     150       -  
Subsidiary obligation in excess of investment                
Investment in AE Advanced Fuels, Inc.     131,432       112,041  
Investment in Aemetis Americas, Inc     205       205  
Investment in Aemetis Biofuels, Inc.     2,738       2,738  
Investment in Aemetis Technologies, Inc.     4,446       4,234  
Investment in Aemetis Property Keyes, Inc.     247       564  
Investment in Aemetis Health Products, Inc.     441       349  
Investment in Goodland Advanced Fuels, Inc.     12,201       8,501  
Investment in Aemetis Biogas LLC     15,918       9,612  
Total subsidiary obligation in excess of investment     167,628       138,244  
                 
Total long term liabilities     167,778       138,244  
                 
Stockholders' deficit                
Series B Preferred convertible stock     1       1  
Common stock     23       21  
Additional paid-in capital     93,426       86,852  
Accumulated deficit     (274,080 )     (237,421 )
Accumulated other comprehensive loss     (4,114 )     (3,825 )
Total stockholders' deficit     (184,744 )     (154,372 )
Total liabilities & stockholders' deficit   $ 7,487     $ 4,511  
Parent Statements of Operations and Comprehensive Loss
    2020     2019  
             
Equity in subsidiary losses   $ (28,820 )   $ (21,745 )
Selling, general and administrative expenses     6,707       6,673  
                 
Operating loss     (35,527 )     (28,418 )
                 
Other expense                
Interest expense     677       1,392  
Other expense     448       5,899  
                 
 Loss before income taxes     (36,652 )     (35,709 )
                 
Income tax expense     7       7  
                 
Net loss     (36,659 )     (35,716 )
                 
Other comprehensive loss                
Foreign currency translation adjustment     (289 )     (249 )
Comprehensive loss   $ (36,948 )   $ (35,965 )
Parent Statements of Cash Flows
    2020     2019  
Operating activities:            
Net loss   $  (36,659 )   $  (35,716 )
Adjustments to reconcile net loss to net cash used in operating activities:                
                 
Stock-based compensation     995       774  
SARs Amortization     -       800  
Depreciation     4       8  
Subsidiary portion of net losses     28,820       21,745  
Change in fair value of SARs liability     -       (82 )
Changes in assets and liabilities:                
Prepaid expenses     38       74  
Accounts payable     (216 )     71  
Accrued interest expense     525       1,184  
Other liabilities     (578 )     5,891  
Other assets     236       (232 )
Net cash used in operating activities     (6,835 )     (5,483 )
                 
Investing activities:                
Subsidiary advances, net     1,332       6,781  
Net cash provided by investing activities     1,332       6,781  
                 
Financing activities:                
Proceeds from borrowings     421       -  
Repayments of borrowings under secured debt facilities     -       (1,298 )
Proceeds from the exercise of stock options     287       -  
Proceeds from issuance of common stock in equity offering     5,113       -  
Net cash provided by (used in) financing activities     5,821       (1,298 )
                 
Net increase in cash and cash equivalents     318       -  
                 
Cash and cash equivalents at beginning of period     -       -  
Cash and cash equivalents at end of period   $ 318     $ -  
                 
Supplemental disclosures of cash flow information, cash paid:                
Interest payments   $ -     $ -  
Income taxes paid     7       8  
                 

 

Supplemental disclosures of cash flow information, non-cash transactions:

 

                
                 
Fair value of warrants issued to subordinated debt holders     181       162  
Exercise of Stock Appreciation Rights added to GAFI debt     -       1,050  
Reclassification of GAFI Non-controlling interest     -       8,501  
Operating lease liabilities arising from obtaining right of use assets      2,632       640